Waters Co. (NYSE:WAT) has been assigned an average recommendation of “Hold” from the fifteen analysts that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $210.54.

WAT has been the subject of several analyst reports. UBS Group lowered their target price on Waters from $248.00 to $230.00 and set a “neutral” rating for the company in a research note on Wednesday, April 24th. Barclays lowered their price objective on Waters from $218.00 to $210.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 24th. ValuEngine cut Waters from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Robert W. Baird lowered their price objective on Waters from $211.00 to $209.00 and set a “neutral” rating for the company in a research report on Wednesday, April 24th. Finally, Zacks Investment Research raised Waters from a “sell” rating to a “hold” rating and set a $217.00 price objective for the company in a research report on Wednesday, May 22nd.

WAT traded up $1.72 on Friday, hitting $207.55. 10,763 shares of the company were exchanged, compared to its average volume of 581,185. Waters has a twelve month low of $167.93 and a twelve month high of $255.21. The stock has a market capitalization of $14.15 billion, a P/E ratio of 25.06, a price-to-earnings-growth ratio of 2.37 and a beta of 1.07. The company has a current ratio of 2.65, a quick ratio of 2.07 and a debt-to-equity ratio of 2.00. The business has a 50-day moving average price of $214.85.

Waters (NYSE:WAT) last released its earnings results on Tuesday, July 30th. The medical instruments supplier reported $2.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.03. Waters had a return on equity of 50.64% and a net margin of 24.09%. The firm had revenue of $599.20 million during the quarter, compared to analysts’ expectations of $601.46 million. During the same period in the previous year, the firm posted $1.95 EPS. Waters’s revenue for the quarter was up .5% on a year-over-year basis. Research analysts forecast that Waters will post 9.01 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of WAT. Fundsmith LLP raised its stake in Waters by 0.9% during the 1st quarter. Fundsmith LLP now owns 5,026,757 shares of the medical instruments supplier’s stock valued at $1,265,285,000 after acquiring an additional 43,498 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Waters by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 1,025,341 shares of the medical instruments supplier’s stock worth $193,104,000 after buying an additional 50,700 shares in the last quarter. Northern Trust Corp raised its stake in shares of Waters by 5.9% during the 1st quarter. Northern Trust Corp now owns 991,892 shares of the medical instruments supplier’s stock worth $249,670,000 after buying an additional 54,938 shares in the last quarter. Champlain Investment Partners LLC raised its stake in shares of Waters by 1.5% during the 1st quarter. Champlain Investment Partners LLC now owns 838,625 shares of the medical instruments supplier’s stock worth $211,090,000 after buying an additional 12,365 shares in the last quarter. Finally, Mawer Investment Management Ltd. raised its stake in shares of Waters by 7.1% during the 2nd quarter. Mawer Investment Management Ltd. now owns 532,219 shares of the medical instruments supplier’s stock worth $114,531,000 after buying an additional 35,506 shares in the last quarter. 96.08% of the stock is owned by institutional investors and hedge funds.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Further Reading: What is the outlook for the FAANG stocks?

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.